Vardenafil Improves Erectile Function in Men with Erectile Dysfunction and Associated Underlying Conditions, Irrespective of the Use of Concomitant Medications
Article first published online: 19 OCT 2009
© 2009 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 7, Issue 1pt1, pages 244–255, January 2010
How to Cite
Eardley, I., Lee, J. C., Shabsigh, R., Dean, J., Maggi, M., Neuser, D. and Norenberg, C. (2010), Vardenafil Improves Erectile Function in Men with Erectile Dysfunction and Associated Underlying Conditions, Irrespective of the Use of Concomitant Medications. Journal of Sexual Medicine, 7: 244–255. doi: 10.1111/j.1743-6109.2009.01547.x
- Issue published online: 5 JAN 2010
- Article first published online: 19 OCT 2009
- Erectile Dysfunction;
- Phosphodiesterase Type 5 Inhibitor;
- Underlying Conditions;
- Concomitant Medications;
- Retrospective Analysis
Introduction. Men with erectile dysfunction (ED) are also likely to have associated underlying conditions.
Aim. This retrospective analysis evaluated the efficacy and safety of vardenafil in men with ED and underlying conditions, including those taking concomitant medications.
Methods. A total of 13 randomized, double-blind, placebo-controlled clinical studies were included. Vardenafil was administered at a starting dose of 10 mg, adjustable to 5 or 20 mg after 4 weeks. Efficacy analyses were performed on the intent-to-treat (ITT) population, using a last observation carried forward approach. Efficacy was assessed for subgroups of patients with diabetes, hypertension, dyslipidemia, or metabolic syndrome (as defined by International Diabetes Federation criteria). Incidence rates of treatment-emergent adverse events were analyzed overall and by subgroup for patients in the safety population.
Main Outcome Measures. Primary efficacy measures were the erectile function domain of the International Index of Erectile Function (IIEF-EF), and Sexual Encounter Profile questions 2 and 3 (SEP2, SEP3).
Results. In total, 4,326 patients were randomized to treatment; the ITT population included 4,143 patients, with 4,266 patients valid for safety. At 12 weeks, vardenafil therapy was associated with statistically significant improvements from baseline in IIEF-EF scores, and SEP2 and SEP3 success rates, including patients with ED and diabetes, hypertension, dyslipidemia, or metabolic syndrome. These improvements were irrespective of level of glycemic control, or use of concomitant medications for the treatment of diabetes, hypertension, or dyslipidemia. Across all subgroups, the number and type of treatment-emergent adverse events were consistent with results from previous studies of phosphodiesterase type 5 inhibitors in men with ED and underlying conditions.
Conclusions. Vardenafil demonstrated favorable efficacy and tolerability in this large pool of patients with ED and underlying conditions. Importantly, the use of concomitant medications was not associated with any noteworthy changes in the efficacy or safety profile of vardenafil. Eardley I, Lee JC, Shabsigh R, Dean J, Maggi M, Neuser D, and Norenberg C. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med 2010;7:244–255.